

Excorp Medical Moves to Minnesota Bioscience Zone

Relocation Offers Tax Advantages and Proximity to University Clinics and Research for Development of Systems to Intervene in Liver Failure

As seen in the Minneapolis Star Tribune and St. Paul Pioneer Press, 22 January 2005

Minneapolis, MN – January 21, 2005 – Excorp Medical, Inc. has moved to the Minnesota Bioscience Zone in the Minneapolis University Research Park. The medical technology company, which has developed an innovative system to sustain life for patients with liver failure, expects the move to advance the company's progress in several ways, according to Daniel G. Miller, Ph.D., the firm's President and Chief Executive Officer.

“Our new facility is close to the clinical and biomedical research facilities of the Minneapolis and St. Paul campuses of the University of Minnesota,” Miller said. “It also provides us with an enhanced research facility and offers ample space for pilot manufacturing operations. Moreover, the Bioscience Zone provides tax advantages that ultimately will lower our cost of capital, and it gives us access to a variety of Minnesota business development programs sponsored by the state.”

Excorp Medical is currently raising additional capital for clinical trials of its technology, which includes a patented bioreactor device that uses liver cells from specially bred pigs to detoxify the blood of patients suffering from liver disease. The system, meant for use in hospitals' intensive care units, is designed to treat patients until their own livers recover or until liver transplants are possible. The company has successfully completed the initial portion of its clinical trials and is planning to continue trials in conjunction with the University of Pittsburgh Medical Center. The company is also engaged in a multi-state search for its first large-scale production plant.

Excorp Medical, Inc. has received FDA Orphan Drug designation for its extracorporeal bioartificial liver system to support patients with advanced liver failure. The company's goal is to be the first firm to introduce a safe, clinically effective bioartificial liver system worldwide. Since its founding in 1995, Excorp Medical has collaborated with the leading liver transplant center at the University of Pittsburgh, advancing the project from initial concept to FDA Phase I/II clinical studies. The market potential for a successful system to treat liver failure is estimated at more than \$7 billion per year in the United States and a comparable amount in Europe.

Excorp Medical, Inc.
739 Kasota Avenue
Minneapolis, MN 55414
www.excorp.com